165 related articles for article (PubMed ID: 36752959)
1. Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
Zhang Y; Noorian F; Abellana R; Rochera J; Herreros A; Antelo G; Lancellotta V; Tagliaferri L; Han Q; Torne A; Rovirosa A
Clin Transl Oncol; 2023 Jun; 25(6):1748-1755. PubMed ID: 36752959
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
[TBL] [Abstract][Full Text] [Related]
3. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
[TBL] [Abstract][Full Text] [Related]
4. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
[TBL] [Abstract][Full Text] [Related]
5. Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
Zhang Y; Ascaso C; Herreros A; Sánchez J; Sabater S; Pino MD; Li Y; Gómez G; Torné A; Biete A; Rovirosa Á
Rep Pract Oncol Radiother; 2020; 25(2):227-232. PubMed ID: 32042274
[TBL] [Abstract][Full Text] [Related]
6. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
Rovirosa A; Valduvieco I; Ascaso C; Herreros A; Bautista C; Romera I; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Feb; 15(2):111-6. PubMed ID: 22855177
[TBL] [Abstract][Full Text] [Related]
7. EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
Lancellotta V; Macchia G; Dinapoli N; Autorino R; Campitelli M; Nardangeli A; Salvati A; Fionda B; Casà C; Cornacchione P; Rovirosa A; Kovács G; Morganti AG; Ferrandina MG; Gambacorta MA; Tagliaferri L
Radiol Med; 2022 Mar; 127(3):341-348. PubMed ID: 35092552
[TBL] [Abstract][Full Text] [Related]
8. EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma.
Zhang Y; Fornes B; Gómez G; Bentoldrà I; Carmona C; Herreros A; Sabater S; Nicolás I; Li Y; Sánchez J; Biete A; Torné A; Ascaso C; Rovirosa Á
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092163
[No Abstract] [Full Text] [Related]
9. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
[TBL] [Abstract][Full Text] [Related]
10. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy.
Small W; Erickson B; Kwakwa F
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1502-7. PubMed ID: 16109462
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
Zhang Y; Rovirosa A; Ascaso C; Herreros A; Torne A; Li Y; Biete A; Sánchez J
Brachytherapy; 2020; 19(1):60-65. PubMed ID: 31587986
[TBL] [Abstract][Full Text] [Related]
12. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules.
Rovirosa A; Ascaso C; Arenas M; Sabater S; Herreros A; Camarasa A; Rios I; Holub K; Pahisa J; Biete A
Radiother Oncol; 2015 Jul; 116(1):143-8. PubMed ID: 26194144
[TBL] [Abstract][Full Text] [Related]
13. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcome of Exclusively Radiographer-led Delivery of Postoperative Vaginal Vault Brachytherapy for Endometrial Cancer - The Addenbrooke's Experience.
Buckley H; Bradshaw K; Gregory D; Prewett S; Tan LT
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):844-849. PubMed ID: 31307862
[TBL] [Abstract][Full Text] [Related]
15. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.
Touboul E; Belkacémi Y; Buffat L; Deniaud-Alexandre E; Lefranc JP; Lhuillier P; Uzan S; Jannet D; Uzan M; Antoine M; Huart J; Ganansia V; Milliez J; Blondon J; Housset M; Schlienger M
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):81-97. PubMed ID: 11316550
[TBL] [Abstract][Full Text] [Related]
16. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
[TBL] [Abstract][Full Text] [Related]
17. [Endometrial adenocarcinoma treated with combined radiotherapy and surgery: 437 cases].
Touboul E; Belkacémi Y; Buffat L; Deniaud-Alexandre E; Lefranc JP; Lhuillier P; Uzan S; Jannet D; Uzan M; Antoine M; Ginesty C; Ganansia V; Jamali M; Milliez J; Blondon J; Schlienger M
Cancer Radiother; 2001 Aug; 5(4):425-44. PubMed ID: 11521391
[TBL] [Abstract][Full Text] [Related]
18. External-beam radiotherapy and/or HDR brachytherapy in postoperative endometrial cancer patients: clinical outcomes and toxicity rates.
De Sanctis V; Agolli L; Valeriani M; Narici S; Osti MF; Patacchiola F; Mossa B; Moscarini M; Maurizi Enrici R
Radiol Med; 2013 Mar; 118(2):311-22. PubMed ID: 22580814
[TBL] [Abstract][Full Text] [Related]
19. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
20. Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.
Rovirosa A; Ascaso C; Sánchez-Reyes A; Herreros A; Abellana R; Pahisa J; Lejarcegui JA; Biete A
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):418-23. PubMed ID: 20800388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
